As highly potent therapies continue to reshape the pharmaceutical landscape, Axplora is strengthening its industrial footprint with a major investment in high-potency active pharmaceutical ingredients (HPAPIs). The company has announced a new milestone in its $60 million expansion programme at its Farmabios site in Gropello Cairoli, Italy.
This move reflects a broader shift in the global drug development pipeline. Highly potent molecules now account for more than 30% of all compounds in development, with over 1,000 candidates currently under investigation—highlighting the growing demand for targeted and complex therapies, particularly in oncology.
At the core of the project is the construction of a new 4,500 m², three-storey R&D and laboratory hub. Designed to accelerate development and scale-up activities, the facility will house state-of-the-art research, quality control and microbiology laboratories, fully integrated with existing manufacturing operations.
By co-locating development, analytical and commercial-scale production capabilities, Axplora aims to significantly reduce the inefficiencies typically associated with multi-site technology transfers. This integrated model is expected to shorten timelines from early-stage development to market supply while improving cost control.
The Farmabios site already plays a central role in Axplora’s HPAPI strategy. It operates one of Europe’s largest high-containment manufacturing workshops, built to OEB 5 standards, with five independent production lines and a total installed capacity of 105 m³. The site supports batch sizes ranging from 0.5 to 300 kilograms, enabling both clinical and commercial-scale production.
This latest investment builds on recent expansions across Axplora’s network, including the enhancement of its Le Mans site in France, a globally recognised facility for antibody-drug conjugates (ADCs) and cytotoxic drug manufacturing. Recent upgrades there have notably strengthened lyophilisation capabilities.
According to CEO Martin Meeson, the investment responds directly to evolving customer expectations. Pharmaceutical companies are increasingly seeking to avoid delays linked to fragmented supply chains, favouring integrated partners capable of delivering speed, reliability and scalability.
Mario Di Giacomo, Managing Director of Farmabios, also emphasised the importance of integrated models in improving timeline predictability and reducing operational complexity.
While the site’s existing HPAPI manufacturing capacity is already fully operational and supporting ongoing projects, the new R&D hub is expected to be completed by February 2027.
Through this expansion, Axplora reinforces its position as a key industrial partner for complex and high-potency modalities, in a market where speed of execution, technical expertise and scalable capacity are becoming critical differentiators.